Spencer Su, MD
Hospitalist · Houston, TXNPI 1851414684
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Amgen$1K
- AstraZeneca$1K
- Vifor Pharma, Inc.$747
- OPKO Pharmaceuticals, LLC$629
- Bayer$625
- plus $3K from 26 others
What the payments were for
- Food & beverage$8,70799%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 57 | $1,175 |
| Amgen(2 entities) | 54 | $1,124 |
| AstraZeneca(2 entities) | 47 | $1,016 |
| Vifor Pharma, Inc. | 44 | $747 |
| OPKO Pharmaceuticals, LLC | 48 | $629 |
| Bayer | 34 | $625 |
| Mallinckrodt Hospital Products Inc. | 20 | $441 |
| Abbott | 3 | $397 |
| Johnson & Johnson | 2 | $253 |
| Travere Therapeutics, Inc. | 12 | $249 |
| Novartis | 10 | $248 |
| Mallinckrodt Enterprises LLC | 8 | $166 |
| ANI Pharmaceuticals, Inc. | 6 | $162 |
| Calliditas Therapeutics US Inc. | 8 | $157 |
| Akebia Therapeutics Inc | 8 | $154 |
| Ardelyx, Inc. | 7 | $152 |
| Boehringer Ingelheim | 2 | $136 |
| Actelion Pharmaceuticals US, Inc. | 1 | $121 |
| Scpharmaceuticals Inc. | 6 | $116 |
| Lilly USA, LLC | 5 | $104 |
| Fresenius USA Marketing, Inc. | 6 | $96 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $87 |
| Cormedix Inc. | 3 | $77 |
| Veloxis Pharmaceuticals, Inc. | 2 | $60 |
| GSK | 3 | $53 |
| Sanofi | 2 | $47 |
| Aurinia Pharma U.S., Inc. | 2 | $44 |
| Apellis Pharmaceuticals, Inc. | 1 | $33 |
| Bolton Medical Inc | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Novo Nordisk | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$258
- XARELTO$253
- CARDIOMEMS$139
- Veltassa$122
- UPTRAVI$121
- OPSUMIT$121
- JARDIANCE$106
- KRYSTEXXA$100
How this compares
$8,766 in reported general payments places this provider in the 95th percentile of 1,284 hospitalist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 24 | $37,241 |
| KerendiaFinerenone | 31 | $31,902 |
| EliquisApixaban | 14 | $8,451 |
| Demeclocycline Hcl | 12 | $1,785 |
| Nifedipine ErNifedipine | 47 | $1,176 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 45 | $866 |
| Magnesium Sulfate | 26 | $645 |
| Tamsulosin Hcl | 41 | $612 |
| Valsartan | 14 | $414 |
| Potassium Chloride | 12 | $362 |
| Carvedilol | 33 | $296 |
| Ondansetron OdtOndansetron | 11 | $278 |
| Losartan Potassium | 23 | $267 |
| Furosemide | 73 | $254 |
| Allopurinol | 26 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $629 | $37,24124 claims |
| BayerKerendia | $625 | $31,90231 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $162 | $41414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 hospitalist providers in Texas.
Other hospitalist in Houston
- Ryan NealHouston$154K
- Ahmad BaroutHouston$44K
- Laxman KalvakuntlaHouston$30K
- Joshua HahnHouston$23K
- Grace OdiHouston$14K
- Martin Chacon PortilloHouston$9K
- Abeer SiddiqiHouston$9K
- Brent GudenkaufHouston$8K
- Dilpreet SinghHouston$7K
- John FlynnHouston$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.